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Abstract—We introduce a nonlinear bi-compartmental dy-
namic tumor cell and supporting vasculature volume growth
model which takes into account nutrient and cell proliferation,
necrosis and angiogenesis. Validation of the model requires
measurement data on tumor volume during the therapy; for
explicit identification of vasculature growth dynamic, in vivo
measurement data on vasculature volume during the therapy
are required as well. We show that the model can be used for
the evaluation of drug dosage protocols.
I. INTRODUCTION
Recently it has been shown by [1] that innovative dosage
delivery methods of anti-angiogenic drugs may be more
effective for treating tumors, compared to conventional anti-
angiogenic dosage protocols. In order to optimize such
therapies with computer methods, we need a computational
model, which is on the one hand capable of the integration
of pathophysiological knowledge and measurement data. On
the other hand, its computational complexity should be at a
tractable level regarding optimization and controller design
purposes. Controller design methodology is unavoidable if
we wish to develop closed loop devices in the future for
personalized tumor treatment purposes [2]. The drawbacks
and shortcomings of models which are suitable for controller
design are summarized in [3]. A common feature of these
models is that either they do not explicitly consider angio-
genesis, or they are far too complex for controller design
[4]. For a recent review of integrative models of vascular
remodeling during tumor growth see [5].
The Hahnfeldt model [6] considers vasculature volume
changes during tumor growth; however, its validity has been
already questioned by new biological results [7]. The model
of Yang [8] considers basic angiogenic processes as well on
a physical basis; however, since the proposed model is based
on concentrations as state-variables, it is unable to describe
tumor geometry and spatial aspects, which are, nevertheless,
the most easiest aspects to measure.
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In this article we propose a new model which explicitly
considers angiogenic processes and the effect of vasculature
volume in the tumor. We suppose that vasculature con-
centration feeds back to tumor development by affecting
the nutrition concentration in the tumor. As the proposed
model takes into account exact geometrical aspect, viz.
tumor volume is calculated, we are able to compare it with
experimental results. Furthermore, we validate the behavior
of the model via its response to various dosage protocols of
anti-angiogenic drug.
The paper is organized as follows. In Section II, we present
the modelling assumptions based on the newest biological
findings; after that the model equations are discussed, par-
ticularly the choice of the variables. In Section III, first model
calibration results based on experimental tumor volume data
are presented, and then the response of the model to different
delivery methods of antiangiogenic drugs are examined. The
paper ends with the conclusions and future works in Section
IV.
II. MATERIAL AND METHODS
A. Modelling Assumptions
Based on the newest biological findings [5], [7], and in
accordance with our previous results [9], modelling assump-
tions are the following:
• We assume spherical tumor geometry, composed of a
core and of a periphery layer.
• Living tumor cells of the periphery proliferate (cellular
mitosis) on a rate which depends on the level of
nutrient reaching them, and on the level of their actual
concentration.
• Tumor cells of the core produce tumor angiogenic factor
(TAF), if the nutrient concentration in the core is low.
• Tumor cells of the core necrotize, if the nutrient con-
centration in the core is too low.
• TAF stimulates new blood vessel formation and vascu-
lature growth in the periphery.
• We assume that processes of cellular responses and
synthesis of various factors (as TAF) are much faster
than growth-related mechanisms.
• As the tumor grows and makes contact with external
vasculature, blood vessels are accumulated in the pe-
riphery and they are partially incorporated from the
environment to the tumor periphery, and then from
tumor periphery to the tumor core.
• We assume that tumor cells basically stay in the same
place; however, as the tumor grows, the same geo-
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metrical position which has been considered earlier as
periphery, will be considered as part of the core.
• We assume that the cells of the core/periphery are
homogeneously distributed in the volume of the
core/periphery.
B. Model Equations
The state equations are as follows
dr
dt
= a1g([TP ]) (1)
dTC
dt
=
dVC
VP
TP − a2fnecr([NC ])TC
dTP
dt
= −
dVC
VP
TP + a3fprol([NP ], [TP ])TP
dTNC
dt
= a2fnecr([GC ])TC (2)
dWC
dt
= a4r
β dVC
VP
WP +
(a5e
−[AI]γAI )fTAF ([NC ])WP (3)
dWP
dt
= dVT ν(r)− a4r
β dVC
VP
WP
+(a5e
−[AI]γAI )fTAF ([NC ])WP (4)
d[AI ]
dt
= −cAI [AI ] + IAI(t) (5)
where r, TC , TP , TNC ,WC ,WP , and [AI] denote the tumor
radius, the number of living tumor cells in the core, the
number of living tumor cells in the periphery, the number of
necrotized tumor cells in the core, the volume of vasculature
in the core, the volume of vasculature in the periphery, and
the concentration of the angiogenic inhibitor respectively.
The variable IAI denotes the injection rate of the angiogenic
inhibitor, considered as input to the system. Square brackets
always denote concentration (or density).
The corresponding units of the model variables can be
found in Table I.
var. r TC TP TNC WC WP [AI]
unit mm - - - mm3 mm3 mg/kg
TABLE I
UNITS OF THE MODEL VARIABLES
The function g([TP ]) describes how the tumor expansion
is derived from the density of tumor cells in the periphery
([TP ]).
g =
1
1 + e
pg−[Tp]
kg
, (6)
where pg and kg are parameters.
The actual tumor volumes of the core and the periphery
are denoted with VC and VP , respectively. The actual volume
increment of the core is dVC , while the actual volume
increment of the tumor is dVT .
VC =
4
3
(dcr)
3
pi (7)
VP =
4
3
(r)3pi − VC (8)
dVC =
4
3
(dc(r + dr))
3
pi − VC (9)
dVT =
4
3
(r + dr)3 −
4
3
r
3
, (10)
where dc denotes the core-periphery ratio; as cells closer to
the tumor center than dcr belong to the core, otherwise they
belong to the periphery. This ratio is a function of the actual
radius r, and always defines an outer layer of approximately
150 µm, which coincides with the diffusion distance [10].
dc(r) = 1.1
(
1
1 + exp( 0.5−r
0.333
)
)2.2
− 0.15. (11)
In this way, the cells of the periphery are always sup-
ported with nutrients and oxygen from the environment. The
vasculature density of the tumor environment is described
as a function of the radius (ν(r)), while γAI denotes the
efficiency of the angiogenic inhibitor. The clearance rate of
the angiogenic inhibitor is cAI , its value is defined following
[11].
We assume that tumor cells basically stay in the same
place; however, as the tumor grows, the same geometrical
position which has been considered earlier as periphery, will
be considered as part of the core. The term dVC
VP
TP (see
(2) and (3)) describes this ’transmission’ of periphery cells
to core cells, since TP
VP
is the density of tumor cells in the
periphery. Consequently, the increment of the core volume
(dVC ) is the volume that is actually internalized from the
periphery to the core.
The term a4r
β dVC
VP
WP in (5) corresponds to the internal-
ization of vasculature from the periphery to the core, which is
supposed to be proportional to rβ where β > 1 is a constant
parameter. This assumption is derived from the geometrical
consideration that the same increment in the radius r causes
a much larger volume growth, if the actual radius is larger,
and the volume which needs blood support is increased more.
Nutrient concentration of the core and the periphery are
[NC ] and [NP ] respectively, these are dimensionless nor-
malized variables. If the nutrient concentration is 1, it is
sufficient for proliferation, i.e. for tumor growth. Nutrient
concentrations may be calculated as
[NC ] =
rC
r
ref
V
(12)
[NP ] =
rP
r
ref
V
, (13)
where rC =
WC
VC
, rP =
WP
VP
and r
ref
V is the reference
vasculature ratio, defining the necessary percentage of blood
vessels in a unit volume of tissue to sufficiently support
tumor cells with nutrients.
The process of proliferation is described by a bi-sigmoid
function (fprol), as proliferation depends on two main fac-
tors. On the one hand, if the concentration of living tumor
cells ([TP ]) is too high, proliferation is limited. On the
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Fig. 1. Cell necrosis (fnecr) and TAF production (fTAF ) as a function
of nutrient concentration of the core ([NC ])
other hand, proliferation is also limited by low nutrient
concentration of the periphery ([NP ]). The function shows
saturation in both variables.
fprol =
1
1 + e
p1−[NP ]
k1
1
1 + e
p2−[TP ]
k2
. (14)
Cell necrosis (fnecr) and TAF production (fTAF ) are
sigmoid functions:
fnecr =
(
1
1 + e
p3−[NC ]
k3
)b3
(15)
fTAF =
(
1
1 + e
p4−[NC ]
k4
)b4
, (16)
where p3, p4, k3, k4, b3 and b4 are parameters. As the nu-
trient concentration decreases, tumor cells begin to produce
TAF in order to start and afterwards enhance vascularization
and get more nutrient; and besides, if the nutrient concen-
tration decreases further, they necrotize (Fig. 1).
Table II summarizes the values and units of the model
parameters.
III. RESULTS
A. Model Calibration Based on Experimental Tumor Volume
Data
Tumor volume data from experimental measurements
[1] were used to calibrate the model. In the experiment
C57Bl/6 mice were implanted with C38 mouse colorectal
carcinoma. Mice C1 - C5 received one 10 mg/kg bolus
of bevacizumab (an angiogenic inhibitor [12]) on day 3
of the experiment. Fig. 2 shows the measured tumor vol-
umes. For model calibration, the initial condition is x(0) =
[0.13 3 495 0 0 0 0 0], the external vasculature
density is ν(r) = 0.002, and the values of the parameters are
described in Table II. Fig. 2 illustrates the calibrated model
which shows good agreement with the experimental tumor
volume data.
parameter value unit
a1 1.2 mm/day
a2 1 mm
3/day
a3 12 1/day
a4 0.06
a5 1 kg/(mg day)
b3 0.3
b4 0.3
cAI log(2)/3.9 1/day
cCDT log(2)/3.9 1/day
k1 0.17
k2 -45000 1/mm
3
k3 -0.04
k4 -0.06
kg 55000 1/mm
3
p1 1
p2 4 10
5 1/mm3
p3 0.2
p4 0.45
pg 4·105 1/mm3
r
ref
V 0.005
β 1.2
γAI 0.8
TABLE II
VALUES AND UNITS OF THE MODEL PARAMETERS
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Fig. 2. Simulated and measured tumor volume data (total simulated volume
refers to V = VP + VC )
In Fig. 3, we can see that at the beginning of the
tumor growth process, vasculature is accumulated in the
periphery at a rate higher than the volume growth of the
periphery, thus the vasculature concentration of the periphery
increases. Later as the radius of the tumor and the term rβ
grows, it is internalized at an increasing rate. TAF-dependent
vascularization (see Fig. 4), which is proportional to the
(constantly increasing) vasculature volume of the periphery,
also contributes to core angiogenesis. However, while these
two mechanisms increase the vasculature volume in the
core, the volume of the core also increases with growth,
as a consequence, the vasculature concentration (vasculature
volume of the core/total volume of the core) of the core is
close to constant (apart from the initial transients, caused
by very small volumes as denominators at the beginning).
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Fig. 3. Simulated vasculature concentrations in the calibrated model
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Fig. 4. Simulated TAF-dependent angiogenesis in the calibrated model –
the term (a5e−[AI]γAI )fTAF ([NC ])WP is depicted
We may clearly see the effect of the anti-angiogenic drug
braking the increasing trend in Fig 3 at day 3.
Fig. 5 depicts tumor cell concentrations in the core and
in the periphery; and necrotized tumor cell concentration in
the core.
B. Model Calibration Based on Response to Different De-
livery Methods of Antiangiogenic Drugs
In [3] two delivery methods of bevacizumab were com-
pared. In the first group, mice received one large dose
according to the prescribed medical protocol; while in the
second group, a significantly smaller dose was applied every
day of the therapy (quasi-continuous therapy). Mice in the
second group received a fraction of what mice received in
the first group in all. The results have shown that the quasi-
continuous therapy was still more effective.
In order to verify these results with the new bi-
compartmental model, we considered the following simu-
lation scenarios (in every case the treatment period was 20
days):
• In Therapy 0, no angiogenic inhibitor was administered.
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Fig. 5. Simulated tumor cell concentrations in the calibrated model
• In Therapy A, we applied one large bolus at day 3,
administrating one-off 10 mg/kg angiogenic inhibitor
(simulation of the prescribed medical protocol).
• In Therapy B, we applied 0.2 mg/kg boluses every day,
thus the total injected amount of angiogenic inhibitor
is 4 mg/kg (simulation of the quasi-continuous therapy
using constant dose/input).
• According to model predictions, we defined one more
quasi-continuous therapy (Therapy C). In this case, the
input (angiogenic inhibitor dose) varies from period to
period. The model predicts that too early injections are
not effective, since angiogenesis is proportional to WP
which is small in the beginning (even if its concentration
may have large peaks). Nevertheless, injections in the
late period are not effective either, since the tumor has
already grown and developed a vasculature in the core.
Consequently, in Therapy C, we applied the following
doses: 0.1 mg/kg in day 1 – day 5, 0.3 mg/kg in day
6 – day 10, 0.25 mg/kg in day 11 – day 15, and 0.15
mg/kg in day 16 – day 20, resulting in a total amount
of 4 mg/kg, similarly to Therapy B.
Table III summarizes the simulation results. Final tumor
volume refers to the value of tumor volume at the end
of the simulation, max([AI]) denotes the maximal value of
the angiogenic inhibitor concentration during the simulation,
while
∫
∞
0
IAI(t) denotes the total administered amount of
angiogenic inhibitor. Note that Therapy A is the same treat-
ment which was used for model calibration, and simulated
tumor volume of Therapy A is shown in Fig. 2.
Simulation results show that the model predictions are
in good agreement with experimental results. The quasi-
continuous administration turns out to be more effective
than the prescribed medical protocol in terms of final tumor
volume, even if the total injected amount of angiogenic
inhibitor was significantly smaller. Moreover, the quasi-
continuous therapy when angiogenic inhibitor dose varies
from period to period (according to model predictions), was
found to be the most effective. In addition, Fig. 6 shows that
in the case of Therapy C, the TAF-dependent angiogenesis
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therapy final tumor volume max([AI])
∫
∞
0
IAI(t)
[mm3] [mg/kg] [mg/kg]
0 5.85 ·103 0 0
A 4.94 ·103 9.62 10
B 4.91 ·103 1.27 4
C 4.76 ·103 1.45 4
TABLE III
SIMULATION RESULTS OF THERAPIES BASED ON DIFFERENT DELIVERY
METHODS
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Fig. 6. Simulated TAF-dependent angiogenesis in the case of Therapy C
is much more slower than in Therapy A (Fig. 4). This means
that quasi-continuous therapy is more effective than one large
bolus dose, not just in terms of final tumor volume, but in
terms of TAF-dependent angiogenesis as well.
IV. CONCLUSIONS AND FUTURE WORKS
A. Conclusions
We proposed a bi-compartmental model describing tumor
cell and supporting vasculature growth dynamics based on
physical principles. The model accounts for conservation
equations regarding tumor cells and vasculature volumes.
A simplified model of nutrient supply by vasculature is
included in the model, as well as angiogenic mechanisms,
which are initiated in the case of low nutrient concentration.
The model has been validated with real experimental data
regarding volume growth, and the explicit consideration
of vasculature volumes makes possible to test it by mea-
surement data. As we have shown, the prediction of the
model regarding one-off bolus and daily quasi-continuous
dosage therapies is in good agreement with the observed
experimental results [1].
B. Future Works
The experimental implementation of the in-silico imple-
mented therapy C may provide further measurement data for
model validation. The other main objective for the future
is further validation of the model with vasculature volume
time series data. On the one hand, tumors implanted in
various tissues with different vascularization may be studied
to compare their growth profile with model predictions.
On the other hand, it would be necessary to continuously
monitor vasculature volumes in the core and the periphery
during tumor growth in the same time with the continuous
measurement of tumor volume.
Other important scenarios are to investigate inhomoge-
neous vasculature environment (variable nutrient concen-
tration), and simulation of combined therapies where not
only an antiangiogenic drug is applied (monotherapy) but
antiangiogenic drug is combined with cytostatic drugs.
V. ACKNOWLEDGMENT
The authors would like to thank the help of Paku Sa´ndor
from the 1st Department of Pathology and Experimental
Cancer Research of the Semmelweis University, Budapest.
REFERENCES
[1] J. Sa´pi, L. Kova´cs, D. A. Drexler, P. Kocsis, D. Gaja´ri, and Z. Sa´pi,
“Tumor volume estimation and quasi-continuous administration for
most effective bevacizumab therapy,” PloS ONE, vol. 10, no. 11, p.
e0142190, 2015.
[2] F. Meric-Bernstam and G. B. Mills, “Overcoming implementation
challenges of personalized cancer therapy,” Nature reviews Clinical
oncology, vol. 9, no. 9, pp. 542–548, 2012.
[3] J. Sa´pi, D. A. Drexler, and L. Kova´cs, “Comparison of mathematical
tumor growth models,” in 2015 IEEE 13th International Symposium
on Intelligent Systems and Informatics (SISY), 2015, pp. 323–328.
[4] Y. Jiang, J. Pjesivac-Grbovic, C. Cantrell, and J. P. Freyer, “A
multiscale model for avascular tumor growth,” Biophysical journal,
vol. 89, no. 6, pp. 3884–3894, 2005.
[5] H. Rieger and M. Welter, “Integrative models of vascular remodel-
ing during tumor growth,” Wiley Interdisciplinary Reviews: Systems
Biology and Medicine, vol. 7, no. 3, pp. 113–129, 2015.
[6] P. Hahnfeldt, D. Panigrahy, J. Folkman, and L. Hlatky, “Tumor
development under angiogenic signaling a dynamical theory of tu-
mor growth, treatment response, and postvascular dormancy,” Cancer
research, vol. 59, no. 19, pp. 4770–4775, 1999.
[7] H. Femke and A. Griffioen, “Tumour vascularization: sprouting an-
giogenesis and beyond,” Cancer Metastasis Rev, vol. 26, no. 3–4, pp.
489–502, 2007.
[8] H. M. Yang, “Mathematical modeling of solid cancer growth with
angiogenesis,” Theoretical Biology and Medical Modelling, vol. 9,
no. 1, p. 1, 2012.
[9] D. Csercsik, J. Sa´pi, and L. Kova´cs, “A bicompartmental dynamic
tumor growth model,” in Proceedings of The 20th World Congress of
the International Federation of Automatic Control, 9-14 July 2017 -
under publication. IFAC, 2017.
[10] S. Redline and N. Berger, Impact of Sleep and Sleep Disturbances on
Obesity and Cancer. Springer-Verlag New York, 2014.
[11] D. A. Drexler, J. Sa´pi, and L. Kova´cs, “A minimal model of tumor
growth with angiogenic inhibition using bevacizumab,” in Proceedings
of The 15th IEEE International Symposium on Applied Machine
Intelligence and Informatics, January 26-28, 2017, Herl’any, Slovakia.
IEEE, 2017.
[12] A. Genentech, “Prescribing information of avastin (bevacizumab),”
http://www.gene.com/download/pdf/avastin prescribing.pdf, 2013,
10.03.2017.
4702
